MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Sarepta Therapeutics Inc

Avatud

SektorTervishoid

61.21 1.06

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

59.75

Max

61.86

Põhinäitajad

By Trading Economics

Sissetulek

125M

159M

Müük

191M

658M

P/E

Sektori keskmine

23.603

57.333

Aktsiakasum

1.9

Kasumimarginaal

24.156

Töötajad

1,372

EBITDA

138M

187M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+140.04% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-5.3B

5.4B

Eelmine avamishind

60.15

Eelmine sulgemishind

61.21

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

Sarepta Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. märts 2025, 14:19 UTC

Suurimad hinnamuutused turgudel

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

20. juuni 2024, 23:05 UTC

Suurimad hinnamuutused turgudel

Sarepta Shares Soar 37% Following Expanded Approval for Elevidys

21. juuni 2024, 08:58 UTC

Peamised uudised

These Stocks Are Moving the Most Today: Microsoft, Nvidia, Trump Media, Sarepta, CarMax, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Sarepta Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

140.04% tõus

12 kuu keskmine prognoos

Keskmine 148.25 USD  140.04%

Kõrge 209 USD

Madal 70 USD

Põhineb 22 Wall Streeti analüütiku instrumendi Sarepta Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

22 ratings

18

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

59.31 / 62.78Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.